{
    "id": 30533,
    "fullName": "CDK4 E184K",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CDK4 E184K lies within the protein kinase domain of the Cdk4 protein (UniProt.org). E184K has been identified in the scientific literature (PMID: 31145688), but has not been biochemically characterized and therefore, its effect on Cdk4 protein is unknown (PubMed, Feb 2020).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 15724,
                    "pubMedId": 31145688,
                    "title": "Next-generation sequencing reveals mutations in RB1, CDK4 and TP53 that may promote chemo-resistance to palbociclib in ovarian cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31145688"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1019,
        "geneSymbol": "CDK4",
        "terms": [
            "CDK4",
            "CMM3",
            "PSK-J3"
        ]
    },
    "variant": "E184K",
    "createDate": "07/17/2019",
    "updateDate": "02/20/2020",
    "referenceTranscriptCoordinates": {
        "id": 180912,
        "transcript": "NM_000075",
        "gDna": "chr12:g.57750738C>T",
        "cDna": "c.550G>A",
        "protein": "p.E184K",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17667,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with metastatic ovarian cancer lacking PTEN expression did not respond to treatment with Ibrance (palbociclib), and was found to harbor RB1 R522* and CDK4 E184K, which potentially contributed to the lack of response (PMID: 31145688).",
            "molecularProfile": {
                "id": 32736,
                "profileName": "CDK4 E184K PTEN neg RB1 R552*"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15724,
                    "pubMedId": 31145688,
                    "title": "Next-generation sequencing reveals mutations in RB1, CDK4 and TP53 that may promote chemo-resistance to palbociclib in ovarian cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31145688"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 32735,
            "profileName": "CDK4 E184K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32736,
            "profileName": "CDK4 E184K PTEN neg RB1 R552*",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 180912,
            "transcript": "NM_000075",
            "gDna": "chr12:g.57750738C>T",
            "cDna": "c.550G>A",
            "protein": "p.E184K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}